Introduction {#sec1-1744806918817429}
============

Increased efforts to avoid the severe side effects known to opioid analgesics are shifting treatment for chronic pain conditions towards non-opioid and interventional therapies. A mounting body of evidence supports the use of spinal cord stimulation (SCS) for its treatment effectiveness and safety.^[@bibr1-1744806918817429][@bibr2-1744806918817429][@bibr3-1744806918817429][@bibr4-1744806918817429]--[@bibr5-1744806918817429]^ Conventional SCS was developed based on the seminal "gate control" theory of pain^[@bibr6-1744806918817429]^ and remains a widely used neurostimulation pain therapy. Conventional SCS involves placement of epidural leads, often at a few levels above (i.e., rostral to) the affected spinal segments that receive noxious inputs (e.g. "pain segments"), and delivery of pulsed electricity to stimulate the dorsal column. Conventional SCS activates low-threshold afferents (i.e., Aβ-fibers) which produces the mild paresthesia (i.e., tingling sensation). Thus, pain inhibition from conventional SCS partially acts through antidromic action potentials in dorsal column fibers to activate inhibitory mechanisms in distal "pain segments" via collateral branches.^[@bibr7-1744806918817429],[@bibr8-1744806918817429]^

Pain inhibitory effects by conventional SCS are intricately linked with spinal mechanisms,^[@bibr9-1744806918817429][@bibr10-1744806918817429]--[@bibr11-1744806918817429]^ as evident by inhibition of neuronal sensitization and nociceptive transmission at spinal level, and changes in release of neurotransmitters and neuromodulators in the spinal cord.^[@bibr11-1744806918817429][@bibr12-1744806918817429][@bibr13-1744806918817429]--[@bibr14-1744806918817429]^ However, the molecular mechanisms which underlie the therapeutic effects of SCS remain unknown. While limited in scope, previous findings suggest that SCS induces broad and prolonged changes in gene expression.^[@bibr15-1744806918817429][@bibr16-1744806918817429]--[@bibr17-1744806918817429]^ To identify new gene networks and molecular pathways altered after repetitive SCS, we conducted the first RNA-seq study of the lumbar spinal cord after repetitive SCS at the T13-L1 level in rats during the maintenance phase of neuropathic pain. To mimic clinical SCS, we applied bi-polar stimulation through a miniature quadripolar electrode which has been validated in previous studies.^[@bibr12-1744806918817429],[@bibr14-1744806918817429],[@bibr18-1744806918817429],[@bibr19-1744806918817429]^ Our findings are consistent with previous reports of an increased immune response associated with SCS. Notably, we also identified downregulation of several genes encoding scaffold proteins located on the postsynaptic membrane in nerve-injured rats after SCS for the first time, which may impact neurotransmission and synaptic efficacy associated with central sensitization. Such transcriptional studies will help explain physiological changes that occur in the spinal cord following repeated SCS after nerve injury and may identify novel therapeutic targets which improve the efficacy of SCS.

Methods {#sec2-1744806918817429}
=======

Animals {#sec3-1744806918817429}
-------

Adult male and female Sprague-Dawley rats (*n* = 12; 12--16 weeks old; Harlan Bioproducts for Science, Indianapolis, IN) were allowed to acclimate for a minimum of 48 h prior to any experimental procedure. The rats were housed separately after implanting the SCS electrode and given access *ad libitum* to food and water. All procedures involving animals were reviewed and approved by the Johns Hopkins Animal Care and are performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Behavior testing {#sec4-1744806918817429}
----------------

Mechanical hypersensitivity was measured using von Frey monofilaments as previously described.^[@bibr12-1744806918817429],[@bibr20-1744806918817429]^ Animals were placed in individual plexiglass cages with a wire mesh floor and allowed to acclimate for 1 h. Response to tactile stimulation to the midplantar surface of the hind paw ipsilateral to the nerve lesion was determined with the up-down method using a series of von Frey monofilaments (0.38, 0.57, 1.23, 1.83, 3.66, 5.93, 9.13, and 13.1 g) as described previously.^[@bibr20-1744806918817429]^ Each monofilament was applied for 4 to 6 s to the test area between the footpads on the plantar surface of each hind paw. Monofilaments with increasing force were applied until a positive response was observed (e.g., abrupt paw withdrawal, shaking, and licking). When a positive response was observed, the monofilament with the next lower force was applied. If a negative response was observed, the next higher force was used. The test continued (1) for five filament applications after a positive test was observed or (2) until the upper or lower end of the von Frey monofilament set was reached. The paw withdrawal threshold (PWT) was determined according to the formula provided by Dixon.^[@bibr21-1744806918817429]^ If a rat did not achieve at least a 50% reduction in baseline (BL) PWT after 48 h or on day 14 following nerve injury, then this animal was considered non-allodynic and excluded from the study.

CCI of sciatic nerve {#sec5-1744806918817429}
--------------------

CCI surgery to the left sciatic nerve was performed on all rats as previously described.^[@bibr22-1744806918817429]^ Under 2% to 3% isoflurane, a small incision was made at the level of the mid-thigh. The sciatic nerve was exposed by blunt dissection through the biceps femoris. Previous studies showed that CCI of sciatic nerve with silk ligatures induced similar infiltration of inflammatory cells and changes in function of the nerve-blood barrier,^[@bibr23-1744806918817429]^ and more stable neuropathic pain behaviors,^[@bibr24-1744806918817429]^ as compared to that induced by chromic gut ligature. Accordingly, the nerve trunk proximal to the distal branching point was loosely ligated with four 4-0 silk sutures placed approximately 0.5 mm apart until the epineurium was slightly compressed and minor twitching of the relevant muscles was observed. The muscle layer was closed with 4-0 silk suture, and the wound closed with metal clips.

Electrode placement and SCS treatment {#sec6-1744806918817429}
-------------------------------------

Animals randomized to receive SCS underwent epidural placement of a sterile, quadripolar SCS electrode (Medtronic Inc.) to the dorsal spinal cord ([Figure 1(a)](#fig1-1744806918817429){ref-type="fig"}). This electrode mimics clinical SCS and was validated in previous studies in rats.^[@bibr12-1744806918817429],[@bibr14-1744806918817429],[@bibr18-1744806918817429],[@bibr19-1744806918817429]^ Under isoflurane anesthesia, a laminectomy was performed at the T13 vertebrae level through which the electrode was inserted epidurally in the rostral direction. The position of the electrode was adjusted so that the contacts were at the T13-L1 spinal cord level which corresponds to the lower thoracic-upper lumbar region. Sutures to the muscle were used to secure the electrode in place, and the proximal end was tunneled subcutaneously and exited the animal at the top of its head for later connection to an external neurostimulator (Model 2100, A-M Systems, Sequim, WA).

![Experimental setup and pain inhibition by SCS. (a) Schematic diagram illustrating the experimental setup. The miniature SCS lead (Medtronic, Minneapolis, MN) was implanted epidurally over the dorsal spinal cord (midline) at the T13-L1 spinal level. Lumbar spinal cord (L4-L6, marked with red lines) tissues ipsilateral to the side of nerve injury were harvest after the last SCS treatment. (b) Upper: Schematic diagram illustrating the experimental timeline. CCI rats (*n* = 5) received the same SCS (red bar, 50 Hz, 80% motor threshold, 0.2 ms, constant current, 120 min/session) from days 36 to 38 post-CCI (two sessions/day) and on day 39 post-CCI (one session). Motor thresholds were measured to 4 Hz stimulation (0.2 ms). Lower: On days 36 to 38 post-CCI, PWTs were measured before (baseline, BL), at 30, 60, and 90 min during SCS (intra-SCS), and at 0, 30, and 60 min after completing SCS in the a.m. session. (c) Average PWTs at 60 and 90 min intra-SCS were significantly increased from pre-SCS baseline on each day. Data are expressed as mean + *SD*. One-way repeated measures ANOVA. \**p*\<0.05 *versus* pre-SCS baseline. (d) To evaluate the peak inhibitory effect of daily SCS on mechanical hypersensitivity in each animal, we averaged PWTs at 60 and 90 min intra-SCS. Then the "Change of intra-SCS PWT" was calculated as follows: Change of intra-SCS PWT = \[(mean intra-SCS PWT) -- (baseline PWT)\]/(baseline PWT) × 100. Scatterplots showed positive linear correlation between change of intra-SCS PWT and motor threshold.\
CCI: chronic constriction injury; PWT: paw withdrawal threshold; SCS: spinal cord stimulation; *SD*: standard deviation.](10.1177_1744806918817429-fig1){#fig1-1744806918817429}

In "twin-pairs" SCS, the first and third contacts of the lead from rostral were set as an anode (+), and the second and fourth were set as a cathode (--). Conventional SCS (50 Hz, 0.2 ms, constant current, and 120 min/session) was applied at an intensity that activated low-threshold A-fibers (80% motor threshold (MoT)), as described in previous studies.^[@bibr12-1744806918817429],[@bibr14-1744806918817429],[@bibr18-1744806918817429],[@bibr19-1744806918817429]^ Before SCS, the MoT for each animal was determined by slowly increasing the current amplitude from zero, until muscle contraction in the mid-lower trunk or hind limbs was observed in response to 4 Hz stimulation at 0.2 ms pulse widths. The rats were then acclimated to the testing environment before the pre-SCS BL PWT was measured.

Experimental design {#sec7-1744806918817429}
-------------------

Our primary goal is to examine the changes of gene expression in the spinal cord after repetitive SCS treatments during the maintenance phase of neuropathic pain. All animals developed mechanical hypersensitivity after CCI and were randomized to receive SCS (CCI + SCS group, *n* = 8) or no treatment (CCI only group, *n* = 4). Rats randomized to the CCI+SCS group were implanted with a SCS electrode and received SCS (50 Hz, 80% MoT, 0.2 ms, constant current, 120 min/session, twice per day) for three consecutive days on days 36 to 38 post-CCI ([Figure 1(b)](#fig1-1744806918817429){ref-type="fig"}). PWTs were measured before BL at 30, 60, and 90 min during SCS (intra-SCS) and at 0, 30, and 60 min after completing SCS in each a.m. session. An additional SCS treatment was given on day 39 post-CCI. Within 1 to 2 h following the last SCS treatment, all animals were euthanized by overdose of isoflurane and decapitation. The ipsilateral lumbar spinal cord (L4-L6 spinal segments) ipsilateral to the nerve lesion was harvested and immediately submerged in DNA/RNA shield solution (Zymo, Irvine, CA) for subsequent RNA extraction. We did not separate the dorsal and ventral half of spinal cord, in order to avoid variations due to different dissections of tissue between different animals.

RNA isolation {#sec8-1744806918817429}
-------------

Total RNA was extracted from the ipsilateral spinal cord with the Quick-RNA MiniPrep Plus kit (Zymo, Irvine, CA) according to manufacturer instructions with on-column DNase I digestion. RNA quantity was measured by the Qubit RNA BR Assay Kit (ThermoScientific, Waltham, MA), and RNA integrity was assessed by the Bioanalyzer RNA Nano Eukaryote kit on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).

RNA-seq library construction and sequencing {#sec9-1744806918817429}
-------------------------------------------

Five hundred nanograms of total RNA per sample were used to construct sequencing libraries (*n* = 1 rat/sample). Strand-specific RNA libraries were prepared using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs Inc., Ipswich, MA) after poly(A) selection by the NEBNext poly(A) mRNA Isolation Module (New England Biolabs Inc., Ipswich, MA) according to manufacturer's instructions. Samples were barcoded using the recommended NEBNext Multiplex Oligos (New England Biolabs Inc., Ipswich, MA). Size range and quality of libraries were verified on the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA-seq libraries were quantified by quantitative polymerase chain reaction using the KAPA library quantification kit (KAPA Biosystems, Wilmington, MA). Each library was normalized to 2 nM and pooled in equimolar concentrations. Paired-end × 150 sequencing was performed on an Illumina HiSeq4000 (Illumina, San Diego, CA). Libraries were pooled and sequenced using two lanes of one HiSeq4000 flow cell to an average depth of 33.6 million reads per sample.

Data analysis {#sec10-1744806918817429}
-------------

Sequencing reads were aligned to annotated RefSeq genes of the rat reference genome (rn6) using HISAT2,^[@bibr25-1744806918817429]^ filtered to remove ribosomal RNA, and visualized using the Integrative Genomics Viewer.^[@bibr26-1744806918817429]^ A gene count matrix that contained raw transcript counts for each annotated gene was generated using the *featureCounts* function of Subread.^[@bibr27-1744806918817429]^ This count matrix was then filtered for low count genes so that only those genes with \>0 reads in each sample were retained. To identify genes that were differentially regulated following SCS, transcript counts were normalized and log~2~ transformed using the default normalization procedures in DESeq2.^[@bibr28-1744806918817429]^ This analysis identified differentially expressed genes between the CCI only and CCI+SCS groups within males or females. The interaction of sex on differential gene expression after injury was evaluated by the interaction term included in the design matrix within DESeq2. All downstream analyses on RNA-seq data were performed on data obtained from DESeq2. Unless otherwise stated an adjusted *p*-value (i.e., false discovery rate (FDR)) \< 0.05 was used to define differentially expressed transcripts between CCI only and CCI+SCS groups. Genes with differential expression between groups were then included in gene ontology (GO) analysis to infer their functional roles and relationships. GO analysis for enriched GO biological processes in each set of differentially enriched genes identified by DESeq2 was performed using ToppGeneSuite (<https://toppgene.cchmc.org>).^[@bibr29-1744806918817429]^ The International Union of Basic and Clinical Pharmacology database (<http://www.guidetopharmacology.org>) was used to assign categories to gene products.^[@bibr30-1744806918817429]^

Results {#sec11-1744806918817429}
=======

SCS attenuated mechanical hypersensitivity in CCI rats {#sec12-1744806918817429}
------------------------------------------------------

Rats that developed mechanical hypersensitivity on the ipsilateral hind paw following CCI were randomized to receive SCS (CCI+SCS, *n* = 8) or not receive SCS treatment (CCI, *n* = 4). Following implantation of the SCS electrode on day 17 after CCI, one male and two female rats showed impaired motor function that required exclusion from the study. The remaining five rats (i.e., two female rats, three male rats) that received SCS showed no adverse events, and data from these rats were included in all analyses. Each SCS treatment was associated with increases in mechanical PWT in the ipsilateral hind paw from pre-SCS BL ([Figure 1(b)](#fig1-1744806918817429){ref-type="fig"}). The peak inhibitory effect of SCS often occurred at 60 and 90 min after start of the SCS and returned to the pre-SCS BL within 30 min of cessation of SCS. The averaged PWTs at 60 and 90 min intra-SCS, which reflect the peak effect of SCS, were significantly increased from pre-SCS BL on each day, *F*(3, 16) = 7.47, *p* = 0.024; [Figure 1(c)](#fig1-1744806918817429){ref-type="fig"}. The change of intra-SCS PWT in individual animals and MoT show a strong correlation, *r*(3) = 0.994, *p* \< 0.001, two-tailed test; [Figure 1(d)](#fig1-1744806918817429){ref-type="fig"}.

Differentially regulated genes in the spinal cord after SCS in male and female CCI rats {#sec13-1744806918817429}
---------------------------------------------------------------------------------------

To determine the effects of SCS on gene expression in the spinal cord that is ipsilateral to the side of nerve injury, we compared RNA-seq data obtained 39 days following CCI to that of rats who received SCS after CCI. Principal component analysis shows segregation of the transcriptomes from CCI rats that received SCS and those that did not receive SCS ([Figure 2(a)](#fig2-1744806918817429){ref-type="fig"}). The first two principal components accounted for a total of 74%. Compared to CCI only rats, the ipsilateral spinal cord from CCI+SCS rats differentially expressed 1113 (7.9%) genes (FDR\<0.05; [Figure 2(b)](#fig2-1744806918817429){ref-type="fig"}). Of these 1113 differentially expressed genes, 785 (70.5%) were upregulated after SCS and 328 (29.5%) were downregulated ([Figure 2(b)](#fig2-1744806918817429){ref-type="fig"}). The genes most significantly up- and downregulated with SCS treatment are listed in [Table 1](#table1-1744806918817429){ref-type="table"} and [Table 2](#table2-1744806918817429){ref-type="table"}, respectively. Of the 1113 differentially expressed genes, 343 genes could be classified into gene classes (i.e., transporters, enzymes, G protein-coupled receptors, ion channels, catalytic receptors, and transcription factors) as defined by International Union of Basic and Clinical Pharmacology ([Figure 2(c)](#fig2-1744806918817429){ref-type="fig"} and Supplemental Figure 1). Mean normalized counts and relative fold change of specific genes that comprise each of these gene classes is shown in Supplemental Figure 1.

![Differential gene expression between CCI rats with and without SCS. (a) Principal component analysis of libraries sequenced for RNA-seq. (b) Volcano plot showing RNA-seq data of ipsilateral L4-L6 spinal cord from CCI rats with and without SCS treatment. DEGs are designated in red and are defined as differentially expressed genes with a FDR \< 0.05. Triangles represent genes with extremely high log~10~FDR or log~2~fold change values. (c) Bar plot showing the numbers of genes differentially expressed genes up- and downregulated by gene class as defined by the IUPHAR (top). Relative expression levels for each rat are shown for each gene class represented in the bar plot (bottom). Up- and downregulated genes are colored in yellow and orange, respectively. Horizontal bars indicate group assignment and sex for each rat.\
CCI: chronic constriction injury; DEG: differentially expressed gene; FDR: false discovery rate; GPCR= G protein-coupled receptor; IC: ion channel; SCS: spinal cord stimulation.](10.1177_1744806918817429-fig2){#fig2-1744806918817429}

###### 

Top 25 genes upregulated in CCI rats after SCS by FDR.

![](10.1177_1744806918817429-table1)

  Ensembl ID           Gene symbol   Full gene name                               Log2 fold change   Standard error   FDR
  -------------------- ------------- -------------------------------------------- ------------------ ---------------- ----------
  ENSRNOG00000046834   C3            Complement component 3                       2.15               0.16             1.77E-35
  ENSRNOG00000046254   Adgre1        Adhesion G protein-coupled receptor E1       1.81               0.18             3.16E-19
  ENSRNOG00000016294   Cd4           CD4 antigen                                  1.51               0.16             2.05E-18
  ENSRNOG00000004649   Il1b          Interleukin 1-beta                           2.46               0.26             1.29E-17
  ENSRNOG00000024899   Cxcl13        Chemokine, CXC Motif, Ligand 13              4.07               0.43             1.68E-17
  ENSRNOG00000020699   Cd37          Leukocyte surface antigen CD37               1.07               0.12             5.84E-15
  ENSRNOG00000013886   Fyb           Fyn-binding protein                          1.54               0.18             1.06E-14
  ENSRNOG00000008816   Gpnmb         Glycoprotein NMB                             1.42               0.17             1.24E-13
  ENSRNOG00000050430   Vav1          VAV1 oncogene                                1.54               0.19             2.73E-13
  ENSRNOG00000042838   Junb          Oncogene JUN-B                               1.27               0.16             3.02E-13
  ENSRNOG00000008409   Myo1f         Myosin IF                                    1.38               0.17             6.89E-13
  ENSRNOG00000018414   Csf1r         Colony-stimulating factor 1 receptor         1.18               0.15             7.67E-13
  ENSRNOG00000043098   Mt2A          Metallothionein 2A                           1.89               0.24             7.67E-13
  ENSRNOG00000015773   Il21r         Interleukin 21 receptor                      2.01               0.25             1.11E-12
  ENSRNOG00000038047   Mt1           Matrix metalloproteinase 14                  2.28               0.29             1.11E-12
  ENSRNOG00000028566   Pld4          Phospholipase D family, member 4             1.16               0.15             1.45E-12
  ENSRNOG00000008465   Tmem176b      LR8 protein                                  1.05               0.13             2.12E-12
  ENSRNOG00000042139   Clec4a1       C-type lectin domain family 4, member a1     1.71               0.22             1.63E-11
  ENSRNOG00000054964   Aoah          Acyloxyacyl hydrolase                        2.60               0.34             2.36E-11
  ENSRNOG00000054860   Clec12a       C-type lectin domain family 12, Member A     1.79               0.24             2.36E-11
  ENSRNOG00000013564   Dok3          Docking protein 3                            1.93               0.26             2.81E-11
  ENSRNOG00000021161   Fermt3        Fermentin family (Drosophila) Homolog 3      1.18               0.16             3.07E-11
  ENSRNOG00000007350   Rac2          Ras-related C3 Botulinum toxin Substrate 2   1.35               0.18             3.07E-11

FDR: false discovery rate.

###### 

Top 25 genes downregulated in CCI rats after SCS by FDR.

![](10.1177_1744806918817429-table2)

  Ensembl ID           Gene symbol   Full gene name                                            Log2 fold change   Standard error   FDR
  -------------------- ------------- --------------------------------------------------------- ------------------ ---------------- ----------
  ENSRNOG00000007112   Pcsk1n        Proprotein convertase subtilisin/kexin type 1 inhibitor   −3.05              0.36             2.93E-14
  ENSRNOG00000017932   St3gal2       ST3 beta-galactoside alpha-2,3-sialyltransferase 2        −0.38              0.07             1.62E-05
  ENSRNOG00000007573   Hoxb9         Homeobox B9s                                              −0.69              0.14             5.53E-05
  ENSRNOG00000016897   Rlbp1         Retinaldehyde-binding protein 1                           −0.57              0.12             1.63E-04
  ENSRNOG00000000501   Zfp523        Zinc finger protein 76                                    −0.40              0.09             1.89E-04
  ENSRNOG00000043390   Samd12        Sterile alpha motif domain contain 12                     −0.48              0.10             1.96E-04
  ENSRNOG00000006649   Thrb          Thyroid hormone receptor beta                             −0.43              0.10             3.21E-04
  ENSRNOG00000002339   Mark1         Microtubule affinity regulating kinase 1                  −0.53              0.12             3.60E-04
  ENSRNOG00000004155   Samd14        Sterile alpha motif domain containing 14                  −0.66              0.15             3.89E-04
  ENSRNOG00000058476   Mast2         Microtubule associated serine/threonine kinase 2          −0.53              0.12             4.24E-04
  ENSRNOG00000037793   Cdk5r2        Cyclin-dependent kinase 5 activator 2                     −0.48              0.11             5.32E-04
  ENSRNOG00000019958   Tmem151b      Transmembrane protein 151B                                −0.91              0.21             5.32E-04
  ENSRNOG00000009772   Kirrel3       Kin of irregular chiasm-like protein 3                    −0.49              0.11             5.99E-04
  ENSRNOG00000048980   Gng2          G protein subunit gamma 2                                 −0.25              0.06             6.09E-04
  ENSRNOG00000018526   Dlg4          Discs large MAGUK scaffold protein 4                      −0.50              0.12             7.77E-04
  ENSRNOG00000023538   Aldh5a1       Aldehyde dehydrogenase 5 family member A1                 −0.49              0.11             7.92E-04
  ENSRNOG00000013408   Npas2         Neuronal PAS domain protein 2                             −0.65              0.15             8.05E-04
  ENSRNOG00000016653   Ngef          Neuronal guanine nucleotide exchange factor               −0.46              0.11             8.31E-04
  ENSRNOG00000019404   Hhatl         Hedgehog acyltransferase-like                             −0.53              0.12             8.52E-04
  ENSRNOG00000010938   Slc7a10       Solute carrier family 7 member 10                         −0.51              0.12             9.41E-04
  ENSRNOG00000008082   Rgs6          Regulator of G protein signaling 6                        −0.55              0.13             1.07E-03
  ENSRNOG00000008145   Traf3         TNF receptor-associated factor 3                          −0.69              0.16             1.07E-03

FDR: false discovery rate.

GO analysis of the upregulated genes showed significant enrichment among a variety immune-related biological process ([Figure 3(a) and (b)](#fig3-1744806918817429){ref-type="fig"}). GO analysis of the downregulated transcripts show significant enrichment among genes involved in synaptic transmission, synaptic organization, and neuron outgrowth ([Figure 4(a) and (b)](#fig4-1744806918817429){ref-type="fig"}). Molecular functional enrichment analysis identified downregulated differentially expressed genes are involved in protein serine/threonine kinase activity and scaffold protein binding (FDR \< 0.005).

![GO biological processes enriched from differentially expressed genes that are upregulated after SCS. (a) The top 25 GO biological processes associated with genes upregulated in CCI+SCS versus CCI only (FDR \< 0.05) as ranked by *p*-value. (b) Heatmap of selected up-regulated genes associated with multiple overrepresented GO biological processes in (a). Data shown are relative expression (i.e., log~2~FC), mean normalized transcript abundance (i.e., log~10~(count+1)), and statistical significance level (i.e., log~10~FDR).](10.1177_1744806918817429-fig3){#fig3-1744806918817429}

![GO biological processes enriched from differentially expressed genes that are downregulated after SCS. (a) The top 25 GO biological processes associated with genes downregulated in CCI+SCS versus CCI only (FDR \< 0.05) as ranked by *p* value. (b) Heatmap of selected downregulated genes associated with the first five overrepresented GO biological processes in (a). Data shown are relative expression (i.e., log~2~FC), mean normalized transcript abundance (i.e., log~10~(count+1)), and statistical significance level (i.e., log~10~FDR).](10.1177_1744806918817429-fig4){#fig4-1744806918817429}

Sex differences associated with differentially regulated genes after SCS of CCI rats {#sec14-1744806918817429}
------------------------------------------------------------------------------------

Next, we explored sex-specific differential gene expression in the spinal cord associated with repetitive SCS. While both males and females showed a significant increase in PWTs during SCS, the PWTs of the female rats were notably lower than the PWTs of the male rats ([Figure 1(b)](#fig1-1744806918817429){ref-type="fig"}). To identify sex-specific changes in gene expression associated with SCS treatment, we compared differentially expressed genes between males and females. Following SCS, male CCI+SCS rats differentially expressed 149 genes (Supplemental Figure 2(a)). Of these 149 differentially expressed genes, 28 (18.8%) were downregulated after SCS and 121 (81.2%) were upregulated. GO analysis of the upregulated genes show enrichment in immune and inflammatory pathways (Supplemental Figure 2(b)). In order to perform GO analysis using downregulated genes, we lowered the statistical significance and used the 380 genes which were downregulated after SCS at an unadjusted *p* \<0.05. GO analysis using this subset of genes showed enrichment in genes involved in synaptic signaling (Supplemental Figure 2(b)).

Female CCI + SCS rats differentially expressed 858 genes following SCS at an FDR \< 0.05 (Supplemental Figure 2(c)). Of these 858 differentially expressed genes, 192 (22.5%) were downregulated after SCS and 666 (77.5%) were upregulated. Similar to males, GO analysis revealed that the upregulated genes were enriched in immune-related processes and downregulated genes were enriched in synaptic signaling-related processes (Supplemental Figure 2(d)). Hierarchical clustering identified segregation of samples by group and then by sex (Supplemental Figure 2(e)). Two genes (i.e., *Eif2s3* and *Cpne4*) showed significantly increased expression in females versus males at an FDR \< 0.05. Expressions of 44 genes were significantly increased in males compared with females (Supplemental Figure 2(f) and Supplemental Table 1).

Discussion {#sec15-1744806918817429}
==========

In this study, we identified the effects of multiple sessions of conventional SCS on gene expression in the lumbar spinal cord ipsilateral to the nerve lesion. We administered SCS to rats during the maintenance phase of neuropathic pain using a custom-made quadripolar electrode, which enabled us to use similar parameters as those used clinically to treat chronic pain.^[@bibr12-1744806918817429],[@bibr18-1744806918817429],[@bibr19-1744806918817429]^ We chose to use rats that received CCI only as our comparison group in an effort to capture all changes that occur in the spinal cord as a result of surgical implantation of the stimulation electrode and subsequent SCS. Consistent with previous findings,^[@bibr12-1744806918817429],[@bibr18-1744806918817429],[@bibr19-1744806918817429]^ conventional SCS at the T13-L1 spinal reduced the mechanical hypersensitivity that developed in the ipsilateral hindpaw of CCI rats. The peak inhibitory effect of SCS often occurred 60 to 90 min after starting the SCS. The pain inhibitory effects on each treatment day varied between individual animals and were similar to those observed in other neuropathic pain models.^[@bibr12-1744806918817429],[@bibr18-1744806918817429],[@bibr19-1744806918817429]^ Pain inhibition by SCS was positively correlated with the MoT. However, the correlation coefficient measures only the degree of linear association between two variables and not causal relationships. Although we included both males and females in our study, we chose to report our analyses after pooling data obtained from both sexes. Only a small number of genes were differentially expressed between sexes, and male and female rats showed similar GO biological processes associated with SCS (Supplemental Figure 2). Future investigation should include a larger sample size to determine if meaningful differences exist in pain inhibition and gene expression between males and females in response to SCS.^[@bibr31-1744806918817429]^

Upregulation of immune-related genes {#sec16-1744806918817429}
------------------------------------

Following nerve injury, a robust immune response is generated as a result of injury and increased neuronal excitability.^[@bibr32-1744806918817429]^ Repetitive SCS at T13-L1 was associated with further increases in the expression of immune-related genes in the lumbar spinal cord of CCI rats ([Figure 3](#fig3-1744806918817429){ref-type="fig"}). These findings are consistent with the only other transcriptome-wide study which reported upregulation of immune-related genes also after SCS.^[@bibr15-1744806918817429]^ Similarly, SCS was associated with altered expression of proteins involved in a variety of immune-related processes (e.g., wound healing and complement) in cerebrospinal fluid of patients with neuropathic pain.^[@bibr33-1744806918817429]^ Immune response and gliosis in the spinal cord after nerve injury are thought to contribute to the maintenance of pathological pain and hyperexcitability of dorsal horn neurons.^[@bibr34-1744806918817429],[@bibr35-1744806918817429]^ Nevertheless, immune responses can also serve to protect the injured area from further insult, contain pathogens, eliminate damaged cells, and initiate repair mechanisms.^[@bibr36-1744806918817429],[@bibr37-1744806918817429]^ The physiological implications of increased expression of immune-related genes in the spinal cord after SCS of nerve-injured rats warrant further investigation.

Central sensitization underlying chronic pain is associated with persistent N-methyl-D-aspartate receptor (NMDAR) sensitization to maintain neuronal hyperexcitability as well as the upregulation of toll-like receptors (TLRs).^[@bibr38-1744806918817429],[@bibr39-1744806918817429]^ To our surprise, in rats with existing CCI to the sciatic nerve, SCS treatment was associated with upregulated TLRs and markers for activated glia. TLR4 is expressed on the cell surface of neurons and immunocompetent cells and can induce a sterile inflammatory response through transcriptional activation of genes that encode key inflammatory mediators (i.e., CCL2/MCP1) as a result of tissue injury/stress.^[@bibr40-1744806918817429]^ We also found significant upregulation of genes encoding markers for astrocytes (i.e., *Gfap* and *Ccl2*) and activated microglia (i.e., *Cd68* and *Itgam*) in the spinal cord following SCS treatments. Activated microglia synthesize and release pro-inflammatory mediators to increase neuronal hyperexcitability following nerve injury.^[@bibr35-1744806918817429]^ Previous studies have reported conflicting evidence regarding the activation of glia in the spinal cord after SCS. Sato et al.^[@bibr16-1744806918817429]^ reported decreased glia activation in the spinal cord following 6 h of SCS for four consecutive days as defined by Itgam and Cd68 protein expression. Recently, increased *Tlr2* and *Cd68* gene expression provided evidence of SCS-induced microglia activation.^[@bibr15-1744806918817429]^ Our findings are consistent with the latter study. We found upregulation of these genes as well as *Gfap* which suggests that SCS is associated with increased activation of immune cells in the spinal cord. Whether upregulation of TLRs, glial activation, and immune-related genes may compromise pain inhibition by SCS warrants further investigation.

Downregulation of γ-aminobutyric acid transporters {#sec17-1744806918817429}
--------------------------------------------------

Despite increased immune responses and glia activation in the spinal cord which may facilitate spinal nociceptive transmission, our animal behavior study found reduction of pain hypersensitivity during each SCS treatment. Thus, the net inhibition of mechanical hypersensitivity by SCS may result from mechanisms other than immune suppression or glial inhibition. The neurochemical mechanisms underlying pain inhibition by conventional SCS include the release of γ-aminobutyric acid (GABA), serotonin, endocannabinoids, acetylcholine, and adenosine into spinal cord.^[@bibr41-1744806918817429][@bibr42-1744806918817429][@bibr43-1744806918817429]--[@bibr44-1744806918817429]^ Uptake of GABA from the presynaptic terminals is required to terminate inhibitory neurotransmission by GABA.^[@bibr45-1744806918817429]^ GAT3 is the GABA transporter expressed on glia that is responsible for the uptake of GABA from the presynaptic terminal and is encoded by *Slc6a11*. Intriguingly, we found that SCS was associated with decreased expression of *Slc6a11*. Thus, a decrease of *Slc6a11* expression by SCS may be a previously uncharacterized mechanism that promotes pain inhibition through increased availability of GABA within the synaptic cleft.

Downregulation of scaffold genes in the postsynaptic membrane {#sec18-1744806918817429}
-------------------------------------------------------------

Changes in synaptic strength between peripheral afferents and second-order neurons underlie central sensitization after nerve injury. This synaptic plasticity is primarily due to activation of NMDAR and localization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) to the postsynaptic membrane,^[@bibr46-1744806918817429]^ which mediate excitatory synaptic transmission of action potentials from peripheral sensory neurons.^[@bibr47-1744806918817429],[@bibr48-1744806918817429]^ Importantly, we found that several genes involved in neurotransmission and synaptic strength were downregulated in CCI rats following SCS treatment. In particular, among those downregulated were genes encoding scaffold proteins located on the postsynaptic membrane.

The postsynaptic membrane of glutamatergic synapses contains a dense network of proteins known as the postsynaptic density (PSD) that stabilizes glutamatergic receptors localization,^[@bibr49-1744806918817429]^ prevents lateral diffusion of the receptors in the postsynaptic membrane,^[@bibr49-1744806918817429]^ and physically links the cytoplasmic domains of receptors to intracellular signaling cascades.^[@bibr50-1744806918817429]^ Therefore, scaffold proteins within the PSD directly affect synaptic plasticity. Scaffold proteins are generally organized into three layers with each containing a specific family of proteins (e.g., Dlg4, Dlgap1-4, and Shank1-3; [Figure 5](#fig5-1744806918817429){ref-type="fig"}). First, *Dlg4* encodes the Dlg4 protein which binds to the intracellular tails of NMDARs,^[@bibr51-1744806918817429]^ promotes aggregation of NMDARs and AMPARs in the PSD,^[@bibr52-1744806918817429]^ and stabilizes AMPAR interactions with its auxiliary proteins.^[@bibr53-1744806918817429]^ Intrathecal knockdown of *Dlg4* expression reduced mechanical and thermal hyperalgesia in rats following L5 spinal nerve ligation.^[@bibr54-1744806918817429],[@bibr55-1744806918817429]^ In addition, *Dlg4*-null mice showed decreased glutamate AMPA receptor-mediated synaptic transmission while NMDA receptors were unaffected.^[@bibr56-1744806918817429]^ Second, *Dlgap1-4* encodes four Dlgap proteins which contain domains (i.e., 14 amino acid repeat domains, DLC, GH1) that interact directly with Dlg4 and Shank proteins.^[@bibr50-1744806918817429],[@bibr57-1744806918817429]^ Altered expression and function of Dlgap proteins is associated with several neurological disorders (e.g., schizophrenia, obsessive compulsive disorder, and autism).^[@bibr50-1744806918817429]^ Altered Dlgap1-4 gene expression after SCS has not been reported. The third layer contains the Shank family of proteins which are encoded by *Shank1-3*. Shank proteins are large scaffold proteins that contain many protein binding domains which enables them to connect to other Shank proteins, glutamate receptors, signaling proteins, and cytoskeletal proteins.^[@bibr58-1744806918817429]^ Increased Shank1 protein expression was found after CCI in the ipsilateral dorsal horn.^[@bibr59-1744806918817429]^ On the other hand, inhibition or siRNA knockdown of *Shank1* in rats after CCI increased mechanical thresholds to pre-injury levels.^[@bibr60-1744806918817429]^ Our findings are consistent with these studies and suggest that repeated SCS treatment is associated with decreased expression of scaffold proteins that are essential for the stability of NMDA and AMPA receptor aggregation and signaling on the postsynaptic membrane (i.e., *Dlg4*, *Dlgap1*, *Dlgap3*, *Shank1*, *Shank3*, *Grip2*; [Figure 5](#fig5-1744806918817429){ref-type="fig"}). NMDA and AMPA signaling underlies the increased synaptic efficacy indicative of central sensitization. Therefore, destabilization of the PSD may represent a novel mechanism for SCS to result in inhibition of spinal synaptic transmission and neuropathic pain.

![Illustration of a glutamatergic synapse between the central terminal of primary sensory neuron and a post-synaptic dorsal horn neuron with and without SCS. *Left:* Nerve injury increases excitatory synaptic transmission. The organization of the PSD by scaffold proteins facilitates this synaptic plasticity which involves AMPAR localization to the post-synaptic membrane, stabilization of membrane receptors, and physical linkage of the cytoplasmic domains of the receptor to intracellular signaling cascades by Dlg4, Dlgap, and Shank proteins. Activation of these intracellular signaling cascades increases intracellular calcium levels and promotes gene transcription. *Right:* RNA-seq data show downregulation of the scaffold proteins that comprise the PSD (e.g., Dlg4, Dlgap1, Dlgap3, Shank1, Shank3, Grip2), which suggest that repeated SCS treatment is associated with destabilization of the PSD in the spinal cord. Decreased expression of these scaffold genes may reduce NMDAR and AMPAR aggregation at the postsynaptic membrane and hence attenuate excitatory synaptic transmission.](10.1177_1744806918817429-fig5){#fig5-1744806918817429}

In summary, we showed that gene expression changes in the spinal cord of nerve-injured rats after multiple SCS sessions, and we identify genes and gene networks differentially impacted by conventional SCS under neuropathic pain conditions. Importantly, several key genes that encode scaffold proteins in the PSD are downregulated following SCS which may destabilize the PSD and decrease efficacy of synaptic signaling. The mechanisms leading to changes in gene expression in distal spinal segments after SCS are unknown. During SCS, antidromic action potentials that travel in the dorsal column fibers can reach caudal spinal segments via collateral branches and induce neurochemical changes. SCS may also activate nearby spinal tracts that affect neurons and glial cells in distal spinal segments. Our current findings provide critical insights into transcriptional pathways induced in the spinal cord by repetitive SCS after nerve injury. Future attempts to increase the therapeutic effects of SCS may involve the combination of conventional SCS with other treatments aimed at specific transcriptional and epigenetic targets.
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